Synergistic effects of combined treatment with histone deacetylase inhibitor suberoylanilide hydroxamic acid and TRAIL on human breast cancer cells

Cancer statistics, 2015

(2015) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy

(2015) Xiaoyun Dai et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

Related articles

(2015)   EXPERT OPINION ON THERAPEUTIC PATENTS

The Synergistic Effect of SAHA and Parthenolide in MDA-MB231 Breast Cancer Cells

(2015) Daniela Carlisi et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Targeting Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (TRAIL): A Promising Therapeutic Strategy in Gliomas

(2015) George A. Alexiou et al.   Seminars in Pediatric Neurology

Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells

(2015) Rachana Trivedi et al.   Frontiers in Oncology

Up-Regulation of P21 Inhibits TRAIL-Mediated Extrinsic Apoptosis, Contributing Resistance to SAHA in Acute Myeloid Leukemia Cells

(2014) Xing Wu et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

Dynamic assessment of cell viability, proliferation and migration using real time cell analyzer system (RTCA)

(2014) Mani Roshan Moniri et al.   CYTOTECHNOLOGY

Anoikis molecular pathways and its role in cancer progression

(2013) Paolo Paoli et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Suberoylanilide Hydroxamic Acid, an Inhibitor of Histone Deacetylase, Enhances Radiosensitivity and Suppresses Lung Metastasis in Breast Cancer In Vitro and In Vivo

(2013) Hui-Wen Chiu et al.   PLoS One

Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed

(2012) Berkley E Gryder et al.   Future Medicinal Chemistry

SAHA/Vorinostat induces the expression of the CD137 receptor/ligand system and enhances apoptosis mediated by soluble CD137 receptor in a human breast cancer cell line

(2012) DANIELA BELLAROSA et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

High Wilms’ tumor 1 mRNA expression correlates with basal-like and ERBB2 molecular subtypes and poor prognosis of breast cancer

(2012) XIAO-WEI QI et al.   ONCOLOGY REPORTS

Tamoxifen-Induced Epigenetic Silencing of Oestrogen-Regulated Genes in Anti-Hormone Resistant Breast Cancer

(2012) Andrew Stone et al.   PLoS One

SAHA/TRAIL combination induces detachment and anoikis of MDA-MB231 and MCF-7 breast cancer cells

(2011) M. Lauricella et al.   BIOCHIMIE

Discovery of N-hydroxy-4-(3-phenylpropanamido)benzamide derivative 5j, a novel histone deacetylase inhibitor, as a potential therapeutic agent for human breast cancer

(2011) Jinhong Feng et al.   CANCER BIOLOGY & THERAPY

BAX unleashed: the biochemical transformation of an inactive cytosolic monomer into a toxic mitochondrial pore

(2011) Loren D. Walensky et al.   TRENDS IN BIOCHEMICAL SCIENCES

Multivalent DR5 Peptides Activate the TRAIL Death Pathway and Exert Tumoricidal Activity

(2010) V. Pavet et al.   CANCER RESEARCH

Benefit of adjuvant chemotherapy in elderly ER-negative breast cancer patients: benefits and pitfalls

(2010) Sandro Barni et al.   Expert Review of Anticancer Therapy

Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer

(2010) Jean-Charles Soria et al.   JOURNAL OF CLINICAL ONCOLOGY

Over Expression ofRhoAis Associated with Progression in Invasive Breast Duct Carcinoma

(2009) Li Ma et al.   Breast Journal

Mechanism of bone metastasis: The role of osteoprotegerin and of the host-tissue microenvironment-related survival factors

(2009) Sofia Fili et al.   CANCER LETTERS

Development of vorinostat: Current applications and future perspectives for cancer therapy

(2009) Victoria M. Richon et al.   CANCER LETTERS

Selective recruitment of breast cancer anti-estrogen resistance genes and relevance for breast cancer progression and tamoxifen therapy response

(2009) Ton van Agthoven et al.   ENDOCRINE-RELATED CANCER

Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice

(2009) S. Shankar et al.   MOLECULAR CANCER THERAPEUTICS

β-Sitosterol sensitizes MDA-MB-231 cells to TRAIL-induced apoptosis

(2008) Cheol PARK et al.   ACTA PHARMACOLOGICA SINICA

TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype

(2008) Monzur Rahman et al.   BREAST CANCER RESEARCH AND TREATMENT

Anoikis resistance and tumor metastasis

(2008) Craig D. Simpson et al.   CANCER LETTERS

Modulation of TRAIL-Induced Apoptosis by HDAC Inhibitors

(2008) Simone Fulda   CURRENT CANCER DRUG TARGETS